Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study
Provided By GlobeNewswire
Last update: Sep 25, 2024
- Patients are preselected for CDKN2A and/or CDKN2B abnormalities -
- Safety and efficacy data to be reported at an upcoming oncology medical conference -
Read more at globenewswire.com3.31
-0.4 (-10.78%)
CYCLACEL PHARMACEUTICALS - CYCC 6 PERP
NASDAQ:CYCCP (7/11/2025, 8:02:39 PM)
Premarket: 5.25 +0.34 (+6.92%)4.91
-0.05 (-1.01%)
Find more stocks in the Stock Screener
CYCC Latest News and Analysis
8 hours ago - ChartmillGet insights into the top gainers and losers of Monday's after-hours session.As the regular session of the US market on Monday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
12 days ago - ChartmillTop movers in Wednesday's sessionStay up-to-date with the latest market trends one hour before the close of the markets on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
13 days ago - ChartmillThese stocks are moving in today's sessionCurious about what's happening in today's session? Check out the latest stock movements and price changes.
13 days ago - ChartmillGapping stocks in Wednesday's sessionLet's delve into the US markets on Wednesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
